Terms: = Sarcomas AND SDHA, SDH2, 6389, ENSG00000073578, FP, P31040, SDHF AND Prognosis
12 results:
1. Hereditary succinate dehydrogenase-deficient renal cell carcinoma.
Rogala J; Zhou M
Semin Diagn Pathol; 2024 Jan; 41(1):32-41. PubMed ID: 37981479
[TBL] [Abstract] [Full Text] [Related]
2. Loss of Chromosome 3q Is a Prognostic Marker in Fusion-Negative Rhabdomyosarcoma.
Dehner CA; Bell RC; Cao Y; He K; Chrisinger JSA; Armstrong AE; Yohe M; Shern J; Hirbe AC
JCO Precis Oncol; 2023 Sep; 7():e2300037. PubMed ID: 37738543
[TBL] [Abstract] [Full Text] [Related]
3. Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma.
DeMartino J; Meister MT; Visser LL; Brok M; Groot Koerkamp MJA; Wezenaar AKL; Hiemcke-Jiwa LS; de Souza T; Merks JHM; Rios AC; Holstege FCP; Margaritis T; Drost J
Nat Commun; 2023 May; 14(1):3074. PubMed ID: 37244912
[TBL] [Abstract] [Full Text] [Related]
4. Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.
Timpanaro A; Piccand C; Uldry AC; Bode PK; Dzhumashev D; Sala R; Heller M; Rössler J; Bernasconi M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768928
[TBL] [Abstract] [Full Text] [Related]
5. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Abbou S; Klega K; Tsuji J; Tanhaemami M; Hall D; Barkauskas DA; Krailo MD; Cibulskis C; Nag A; Thorner AR; Pollock S; Imamovic-Tuco A; Shern JF; DuBois SG; Venkatramani R; Hawkins DS; Crompton BD
J Clin Oncol; 2023 May; 41(13):2382-2393. PubMed ID: 36724417
[TBL] [Abstract] [Full Text] [Related]
6. Serine hydroxymethyltransferase 2 expression promotes tumorigenesis in rhabdomyosarcoma with 12q13-q14 amplification.
Nguyen TH; Vemu PL; Hoy GE; Boudjadi S; Chatterjee B; Shern JF; Khan J; Sun W; Barr FG
J Clin Invest; 2021 Aug; 131(15):. PubMed ID: 34166228
[TBL] [Abstract] [Full Text] [Related]
7. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
[TBL] [Abstract] [Full Text] [Related]
8. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
[TBL] [Abstract] [Full Text] [Related]
9. FAK Signaling in Rhabdomyosarcoma.
Perrone C; Pomella S; Cassandri M; Braghini MR; Pezzella M; Locatelli F; Rota R
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182556
[TBL] [Abstract] [Full Text] [Related]
10. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
[TBL] [Abstract] [Full Text] [Related]
12. Pelvic Ewing sarcoma: a retrospective analysis of 241 cases.
Hoffmann C; Ahrens S; Dunst J; Hillmann A; Winkelmann W; Craft A; Göbel U; Rübe C; Voute PA; Harms D; Jürgens H
Cancer; 1999 Feb; 85(4):869-77. PubMed ID: 10091764
[TBL] [Abstract] [Full Text] [Related]
